Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352927 | 0.89 | LMNA (0.43) | LMNAHSD17B10FDPSALDH1A1MEN1 | |
| SCHEMBL3084004 | 0.83 | ALOX15 (0.36) | LMNAHSD17B10ALDH1A1MEN1CYP1A2 | |
| SCHEMBL22561293 | 0.82 | LMNA (0.39) | LMNAHSD17B10FDPSALDH1A1MEN1 | |
| SCHEMBL12611360 | 0.82 | LMNA (0.39) | LMNAHSD17B10FDPSALDH1A1ALOX15 | |
| SCHEMBL28212588 | 0.81 | FDPS (0.44) | FDPS | |
| Hydrochloric Acid SCHEMBL4402725 | 0.80 | ALOX15 (0.35) | LMNAHSD17B10ALDH1A1MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11512823 | 0.80 | ALOX15 (0.35) | LMNAHSD17B10ALDH1A1MEN1CYP1A2 | |
| SCHEMBL3417933 | 0.78 | ALOX15 (0.33) | LMNAALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL1033008 | 0.76 | ALDH1A1 (0.38) | LMNAHSD17B10FDPSALDH1A1MEN1 | |
| SCHEMBL8604881 | 0.76 | KMT2A (0.38) | LMNAALDH1A1MEN1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097043-A1 | ANTIBODIES FOR TARGETING PSMA AND CD28 AND USES THEREOF | Janux Therapeutics, Inc. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-3972580-A1 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2022-03-30 | — | — | EP | disclosed |
| US-20220071938-A1 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY | RECORDATI S.P.A. (IT) | 2022-03-10 | — | — | US | disclosed |
| US-20220040129-A1 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY | RECORDATI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071938-A1 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY | OAT, GLS, OTC | LMNA 1844/4885HSD17B10 1129/4885FDPS 4216/4885 |
| US-20220040129-A1 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY | OAT, GLS, OTC | LMNA 1844/4885HSD17B10 1129/4885FDPS 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.